Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002173 · ClinicalTrials.gov registry record · NA

An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.

A NA study of HIV Infections, sponsored by The Immune Response Corporation.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002173: Completed NA study of HIV Infections, sponsored by The Immune Response Corporation.

NCT00002173 is a NA study of HIV Infections that has completed, run by The Immune Response Corporation. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002173, a NA study of HIV Infections, has completed, sponsored by The Immune Response Corporation.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

To provide an alternative therapy to HIV-infected patients for whom there is no comparable or satisfactory alternative drug or therapy available.

Conditions Studied

HIV Infections

Interventions

  • BIOLOGICAL HIV-1 Immunogen

Study Locations (1)

California

  • Immune Response Corp - Carlsbad

Trial Details

FieldValue
Phase NA
The Immune Response Corporation

3 total trials

What the finished NCT00002173 record still lists

NCT00002173 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which HIV-1 Immunogen is the first listed.

NCT00002173 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00002173 about?

NCT00002173 is a clinical study titled "An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.". To provide an alternative therapy to HIV-infected patients for whom there is no comparable or satisfactory alternative drug or therapy available.

What is the current status of trial NCT00002173?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002173 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002173?

The interventions under investigation include: HIV-1 Immunogen (BIOLOGICAL).

Who is sponsoring clinical trial NCT00002173?

This trial is sponsored by The Immune Response Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002173 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002173, the US trial registry maintained by the National Library of Medicine. NCT00002173 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.